289 related articles for article (PubMed ID: 24130766)
1. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
[TBL] [Abstract][Full Text] [Related]
2. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
3. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for GPR40 allosteric agonism and incretin stimulation.
Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C
Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780
[TBL] [Abstract][Full Text] [Related]
5. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
[TBL] [Abstract][Full Text] [Related]
6. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
[TBL] [Abstract][Full Text] [Related]
7. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
8. Fasiglifam (TAK-875) has dual potentiating mechanisms via Gαq-GPR40/FFAR1 signaling branches on glucose-dependent insulin secretion.
Sakuma K; Yabuki C; Maruyama M; Abiru A; Komatsu H; Negoro N; Tsujihata Y; Takeuchi K; Habata Y; Mori M
Pharmacol Res Perspect; 2016 Jun; 4(3):e00237. PubMed ID: 27433346
[TBL] [Abstract][Full Text] [Related]
9. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
[TBL] [Abstract][Full Text] [Related]
10. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
Li Z; Zhou Z; Zhang L
Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
[No Abstract] [Full Text] [Related]
11. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
12. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
13. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates.
Rady B; Liu J; Huang H; Bakaj I; Qi J; Lee SP; Martin T; Norquay L; Player M; Pocai A
Front Endocrinol (Lausanne); 2022; 13():1061688. PubMed ID: 36482991
[TBL] [Abstract][Full Text] [Related]
14. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
Lin DC; Guo Q; Luo J; Zhang J; Nguyen K; Chen M; Tran T; Dransfield PJ; Brown SP; Houze J; Vimolratana M; Jiao XY; Wang Y; Birdsall NJ; Swaminath G
Mol Pharmacol; 2012 Nov; 82(5):843-59. PubMed ID: 22859723
[TBL] [Abstract][Full Text] [Related]
15. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
Mohammad S
Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
[TBL] [Abstract][Full Text] [Related]
16. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
[TBL] [Abstract][Full Text] [Related]
17. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
18. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
19. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant CF
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
[TBL] [Abstract][Full Text] [Related]
20. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
